15.07.2014 Views

Form 20-F 2005

Form 20-F 2005

Form 20-F 2005

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

in August and November, the European potable water treatment operations of the Eco Services enterprise to Feralco AB<br />

and Novasep, respectively;<br />

in August, the North American phosphates business of the Novecare enterprise to Bain Capital;<br />

in November, the chlorine production business, located in Staveley (United Kingdom) of the Novecare enterprise to Ineos<br />

Chlore Ltd.; and<br />

in December, the anesthetics business of the Organics enterprise to Nicholas Piramal India Ltd.<br />

Disposals completed in <strong>20</strong>05 generated a net loss of €46 million before tax, while disposals completed in <strong>20</strong>04 generated a<br />

€216 million net gain before tax, with the income tax charge amounting to €22 million.<br />

In addition, in December <strong>20</strong>04, we acquired the Chloralp Group from LaRoche Industries. As a result of the acquisition, the Chloralp<br />

Group, Cevco and GIE Spiral, which were previously accounted for by the equity method, became fully consolidated.<br />

The main businesses in the process of being sold as of December 31, <strong>20</strong>05 were:<br />

Nylstar: this 50% owned entity was classified under discontinued operations in <strong>20</strong>04, pursuant to our commitment to a<br />

disposal in connection with our withdrawal from the European textile business of Polyamide. We expect that the negotiations<br />

under way with the Radici group should lead to a sale in <strong>20</strong>06;<br />

decorative coatings and adhesives (latex business): in November <strong>20</strong>05, this Coatis segment business was subject to a sales<br />

agreement with Hexion Specialty Chemicals Inc. and the disposal was completed in January <strong>20</strong>06;<br />

development and custom synthesis for the pharmaceuticals industry: in December <strong>20</strong>05, Rhodia signed a letter of intent<br />

with Shasun Chemicals & Drug Ltd. with a view to selling this Rhodia Pharma Solutions segment business and the disposal<br />

was completed in March <strong>20</strong>06;<br />

spanish phosphates production business of the Corporate and Others segment: after having withdrawn from the phosphates<br />

production business at Rieme in Belgium, we have been negotiating actively our withdrawal from this business since the<br />

end of <strong>20</strong>05.<br />

Critical Accounting Estimates<br />

The Consolidated Financial Statements were prepared for the first time in accordance with IFRS (International Financial Reporting<br />

Standards), as adopted by the European Union. IFRS accounting standards include IFRS, IAS (International Accounting Standards)<br />

and IFRIC (International Financial Reporting Interpretations Committee) interpretations. The standards and interpretations adopted<br />

for the preparation of the <strong>20</strong>05 Consolidated Financial Statements and the <strong>20</strong>04 comparative financial statements are those<br />

published in the Official Journal of the European Union (“OJEU”) at December 31, <strong>20</strong>05 and whose application is mandatory as<br />

of this date and those standards and interpretation which Rhodia has chosen to apply early. The principles adopted with respect<br />

to the implementation of IFRS 1 First-time adoption of international financial reporting standards and the impacts arising from the<br />

differences from the French accounting principles previously applied to the Group’s financial condition, results of operations and<br />

cash flows are analyzed in Note 38 to the Consolidated Financial Statements. See Note 2 to the Consolidated Financial Statements<br />

for additional information on our principal accounting methods.<br />

The preparation of Consolidated Financial Statements requires us to make estimates that may affect the reported value of assets,<br />

liabilities, income, expense and commitments. We believe that the accounting estimates we use are reasonable. However, the actual<br />

amounts may differ from these estimates since even the best estimates require certain adjustments. Accordingly, we review the<br />

accounting estimates used to prepare our Consolidated Financial Statements on a regular basis to ensure that they are reasonable.<br />

Changes in these estimates may require us to record higher or lower expenses and may have a favorable or unfavorable impact<br />

on our financial condition and cash flows. Final amounts are likely to differ from the estimates used in preparing the financial<br />

statements.<br />

<strong>Form</strong> <strong>20</strong> - F <strong>20</strong>05 - Rhodia<br />

39

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!